These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 29969606)

  • 1. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
    Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
    Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
    Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
    Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
    Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
    Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer.
    Gordetsky JB; Montgomery KW; Giannico GA; Rais-Bahrami S; Thapa P; Boorjian S; Frank I; Cheville J
    Int J Surg Pathol; 2022 Feb; 30(1):6-14. PubMed ID: 34180731
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
    Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
    Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients' samples.
    Gulinac M; Dikov D; Velikova T; Belovezhdov V
    Ann Diagn Pathol; 2020 Dec; 49():151640. PubMed ID: 33069081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
    de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
    Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.
    Tretiakova M; Fulton R; Kocherginsky M; Long T; Ussakli C; Antic T; Gown A
    Mod Pathol; 2018 Apr; 31(4):623-632. PubMed ID: 29271413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
    Eckstein M; Erben P; Kriegmair MC; Worst TS; Weiß CA; Wirtz RM; Wach S; Stoehr R; Sikic D; Geppert CI; Weyerer V; Bertz S; Breyer J; Otto W; Keck B; Burger M; Taubert H; Weichert W; Wullich B; Bolenz C; Hartmann A; Erlmeier F
    Eur J Cancer; 2019 Jan; 106():234-243. PubMed ID: 30528808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors.
    Plage H; Furlano K; Hofbauer S; Weinberger S; Ralla B; Franz A; Fendler A; de Martino M; Roßner F; Elezkurtaj S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Zecha H; Minner S; Simon R; Sauter G; Weischenfeldt J; Klatte T; Schlomm T; Horst D; Schallenberg S
    BMC Urol; 2024 Apr; 24(1):96. PubMed ID: 38658905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer.
    Debatin NF; Bady E; Mandelkow T; Huang Z; Lurati MCJ; Raedler JB; Müller JH; Vettorazzi E; Plage H; Samtleben H; Klatte T; Hofbauer S; Elezkurtaj S; Furlano K; Weinberger S; Giacomo Bruch P; Horst D; Roßner F; Schallenberg S; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke TH; Hallmann S; Koch S; Adamini N; Lennartz M; Minner S; Simon R; Sauter G; Zecha H; Schlomm T; Blessin NC
    Eur Urol; 2024 Jul; 86(1):42-51. PubMed ID: 38383257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
    Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
    Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
    Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
    Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
    Coppock JD; Volaric AK; Mills AM; Gru AA
    Hum Pathol; 2018 Dec; 82():282-288. PubMed ID: 30075155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.
    Necchi A; Madison R; Raggi D; Jacob JM; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Huang R; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Alexander BM; Grivas P; Ross JS
    Eur Urol; 2020 Apr; 77(4):548-556. PubMed ID: 31959546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H3 expression in upper tract urothelial carcinoma associates with adverse clinicopathological features and poor survival.
    Koyama Y; Morikawa T; Miyama Y; Miyakawa J; Kawai T; Kume H; Sawabe M; Ushiku T
    Pathol Res Pract; 2020 Dec; 216(12):153219. PubMed ID: 33049447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.